Formulation. The formulation of BL-1040 is shown in Table 5.1. Table 5.1 Formulation of BL-1040
Formulation. The Annual Performance Bonus will be determined from Employer's earnings before state and federal taxes ("Before Tax Earnings"). The Board shall each year during the term of this Agreement establish a Performance Bonus Criteria (herein so called) which shall be Employer's budgeted Before Tax Earnings for that year and which shall not be less than the Performance Bonus Criteria for the immediately preceding year.
Formulation. Genentech and/or its Affiliates or sublicensee(s) shall be responsible for formulating such Genentech Products and shall bear all associated costs.
Formulation. Renovis and/or its sublicensee(s) shall be responsible for formulating such Renovis Products and shall bear all associated costs.
Formulation. The term "Formulation" is defined in Section 3.01(i) below.
Formulation. Genentech and/or its sublicensee(s) shall be responsible for formulating such Lead Products and shall bear all associated costs.
Formulation. Formulation Services may be purchased by Buyer from Seller as reflected in Buyer’s Purchase Order for Goods. All Formulas shall be owned by Buyer unless otherwise expressly stated in writing. At times Seller may perform preliminary formulation testing such as thermal cycling for an initial stability screen on the Formula. This initial screen is no more than a screen; it shall not create any representation or warranty by the Seller of the short/long term performance of the Formula. All liability for claims made regarding the Formulas/Goods are the responsibility of Buyer. This includes but is not limited to claims pertaining to expiration, stability, organic, animal testing (or “cruelty free”), parabens, vegan, heavy metal content or any other claims relating to Formula content or product performance.
Formulation. The unilateral generation of ideas and concepts by management not yet communicated to the Union for their remarks and consideration. Such communication to the Union must take place prior to implementation.
Formulation. 2.1.2.2.3.1 Sarepta shall generate internally, the development of a formulation method of the API, AVI-7288, [†††] Decision: [†††]
Formulation. At the current time, it is anticipated that the DP formulation will be based on [**] will be evaluated [**]. Conditions for the optimum [**] will be determined and these initial experiments will be carried out using protein prepared from the in-house skeleton process. Once material manufactured at the CMO is available, formulation experiments will be repeated using the knowledge gained from the initial formulation development work using the early material from the skeleton process. The formulation process will then be transferred to a secondary manufacturer for the manufacture of transfer, toxicology and clinical batches of DP.
